Susceptibility to myocardial ischemia reperfusion injury at early stage of type 1 diabetes in rats

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Li, Haobo ^a   Liu, Zipeng ^a   Wang, Junwen ^a,b   Wong, Gordon T ^a   Cheung, Chi Wai ^a,b   Zhang, Liangqing ^c   Chen, Can ^c   Xia, Zhengyuan ^a,b,c   Irwin, Michael G ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Infarct size; Ischemia reperfusion injury

Indexed keywords

3 NITROTYROSINE; CASPASE 3; CREATINE KINASE MB; ISOPROSTANE DERIVATIVE; LACTATE DEHYDROGENASE; NITRIC OXIDE; PROTEIN KINASE B; STAT3 PROTEIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRIPHENYLTETRAZOLIUM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY LIGATION; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; HEART FUNCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NICK END LABELING; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BIOLOGICAL MARKERS; CASPASE 3; CREATINE KINASE, BB FORM; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DINOPROST; GLYCOGEN SYNTHASE KINASE 3; L-LACTATE DEHYDROGENASE; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE; OXIDATIVE STRESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; STAT3 TRANSCRIPTION FACTOR; STROKE VOLUME; SUPEROXIDE DISMUTASE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 84883861274     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-133     Document Type: Article

References (39)

1. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, Luepker RV. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med 1996, 334(14):884-890. 10.1056/NEJM199604043341403, 8596571.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339(4):229-234. 10.1056/NEJM199807233390404, 9673301.
3. Alegria JR, Miller TD, Gibbons RJ, Yi QL, Yusuf S. Collaborative Organization of RheothRx Evaluation Trial I: infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am Heart J 2007, 154(4):743-750. 10.1016/j.ahj.2007.06.020, 17893003.
4. Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, et al. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol 2007, 100(2):206-210. 10.1016/j.amjcard.2007.02.080, 17631071.
5. Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Euro Heart J 1988, 9(3):259-264.
6. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993, 22(7):1788-1794. 10.1016/0735-1097(93)90758-S, 8245329.
7. Engbersen R, Riksen NP, Mol MJ, Bravenboer B, Boerman OC, Meijer P, Oyen WJ, Tack C, Rongen GA, Smits P. Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: a pilot study. Cardiovas Diabetol 2012, 11:124.
8. Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal 2011, 14(5):781-790. 10.1089/ars.2010.3343, 3052273, 20578962.
9. Ravingerova T, Neckar J, Kolar F. Ischemic tolerance of rat hearts in acute and chronic phases of experimental diabetes. Mole Cell Biochem 2003, 249(1-2):167-174.
10. Xu G, Takashi E, Kudo M, Ishiwata T, Naito Z. Contradictory effects of short- and long-term hyperglycemias on ischemic injury of myocardium via intracellular signaling pathway. Exp Mole Pathol 2004, 76(1):57-65.
11. Li H, Bian Y, Zhang N, Guo J, Wang C, Lau WB, Xiao C. Intermedin protects against myocardial ischemia-reperfusion injury in diabetic rats. Cardiovas Diabetol 2013, 12(1):91.
12. Wang T, Mao X, Li H, Qiao S, Xu A, Wang J, Lei S, Liu Z, Ng KF, Wong GT, et al. N-Acetylcysteine and allopurinol up-regulated the Jak/STAT3 and PI3K/Akt pathways via adiponectin and attenuated myocardial postischemic injury in diabetes. Free Rad Biol Med 2013, 63C:291-303.
13. Lopaschuk GD, Saddik M, Barr R, Huang L, Barker CC, Muzyka RA. Effects of high levels of fatty acids on functional recovery of ischemic hearts from diabetic rats. Am J Physiol 1992, 263(6 Pt 1):E1046-E1053.
14. Paulson DJ, Shug AL, Zhao J. Protection of the ischemic diabetic heart by L-propionylcarnitine therapy. Mole Cell Biochem 1992, 116(1-2):131-137.
15. Marfella R, D'Amico M, Di Filippo C, Piegari E, Nappo F, Esposito K, Berrino L, Rossi F, Giugliano D. Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia 2002, 45(8):1172-1181. 10.1007/s00125-002-0882-x, 12189448.
16. Ma G, Al-Shabrawey M, Johnson JA, Datar R, Tawfik HE, Guo D, Caldwell RB, Caldwell RW. Protection against myocardial ischemia/reperfusion injury by short-term diabetes: enhancement of VEGF formation, capillary density, and activation of cell survival signaling. Naunyn-Schmiedeberg's Arch Pharmacol 2006, 373(6):415-427. 10.1007/s00210-006-0102-1, 14053546.
17. Ansley DM, Wang B. Oxidative stress and myocardial injury in the diabetic heart. J Pathol 2012,
18. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congestive Heart Failure (Greenwich, Conn) 2002, 8(3):132-140.
19. Finkel T. Signal transduction by reactive oxygen species in non-phagocytic cells. J Leukocyte Biol 1999, 65(3):337-340.
20. Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME, Kerendi F, Guyton RA, Vinten-Johansen J. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004, 62(1):74-85. 10.1016/j.cardiores.2004.01.006, 15023554.
21. Wang T, Qiao S, Lei S, Liu Y, Ng KF, Xu A, Lam KS, Irwin MG, Xia Z. N-acetylcysteine and allopurinol synergistically enhance cardiac adiponectin content and reduce myocardial reperfusion injury in diabetic rats. PLoS One 2011, 6(8):e23967. 10.1371/journal.pone.0023967, 3166050, 21912612.
22. Thirunavukkarasu M, Juhasz B, Zhan L, Menon VP, Tosaki A, Otani H, Maulik N. VEGFR1 (Flt-1+/-) gene knockout leads to the disruption of VEGF-mediated signaling through the nitric oxide/heme oxygenase pathway in ischemic preconditioned myocardium. Free Rad Biol Med 2007, 42(10):1487-1495. 10.1016/j.freeradbiomed.2007.02.011, 1924469, 17448895.
23. Xu Y, Huo Y, Toufektsian MC, Ramos SI, Ma Y, Tejani AD, French BA, Yang Z. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circulatory Physiol 2006, 290(2):H692-699.
24. Redel A, Jazbutyte V, Smul TM, Lange M, Eckle T, Eltzschig H, Roewer N, Kehl F. Impact of ischemia and reperfusion times on myocardial infarct size in mice in vivo. Exp Biol Med (Maywood, NJ) 2008, 233(1):84-93.
25. Turer AT, Mahaffey KW, Gallup D, Weaver WD, Christenson RH, Every NR, Ohman EM. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovas Med 2005, 6:12.
26. Christenson RH, Vollmer RT, Ohman EM, Peck S, Thompson TD, Duh SH, Ellis SG, Newby LK, Topol EJ, Califf RM. Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI study group. Am J Cardiol 2000, 85(5):543-547. 10.1016/S0002-9149(99)00808-5, 11078264.
27. Xia Z, Kuo KH, Godin DV, Walker MJ, Tao MC, Ansley DM. 15-F(2t)-isoprostane exacerbates myocardial ischemia-reperfusion injury of isolated rat hearts. Am J Physiol Heart Circulatory Physiol 2005, 289(4):H1366-1372.
28. Preuss KC, Gross GJ, Brooks HL, Warltier DC. Time course of recovery of " stunned" myocardium following variable periods of ischemia in conscious and anesthetized dogs. Am Heart J 1987, 114(4 Pt 1):696-703.
29. Hasche ET, Fernandes C, Freedman SB, Jeremy RW. Relation between ischemia time, infarct size, and left ventricular function in humans. Circulation 1995, 92(4):710-719. 10.1161/01.CIR.92.4.710, 7641348.
30. Galinanes M, Fowler AG. Role of clinical pathologies in myocardial injury following ischaemia and reperfusion. Cardiovas Res 2004, 61(3):512-521.
31. Di Filippo C, Cuzzocrea S, Rossi F, Marfella R, D'Amico M. Oxidative stress as the leading cause of acute myocardial infarction in diabetics. Cardiovas Drug Rev 2006, 24(2):77-87.
32. Schulz R, Aker S, Belosjorow S, Heusch G. TNFalpha in ischemia/reperfusion injury and heart failure. Basic Res Cardiol 2004, 99(1):8-11. 10.1007/s00395-003-0431-x, 14685700.
33. Gu Q, Yang XP, Bonde P, DiPaula A, Fox-Talbot K, Becker LC. Inhibition of TNF-alpha reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog. J Cardiovas Pharmacol 2006, 48(6):320-328.
34. Xia Z, Guo Z, Nagareddy PR, Yuen V, Yeung E, McNeill JH. Antioxidant N-acetylcysteine restores myocardial Mn-SOD activity and attenuates myocardial dysfunction in diabetic rats. Euro J Pharmacol 2006, 544(1-3):118-125.
35. Xia Z, Vanhoutte PM. Nitric oxide and protection against cardiac ischemia. Curr Pharm Des 2011, 17(18):1774-1782. 10.2174/138161211796391047, 21631419.
36. Akhtar S, Yousif MHM, Chandrasekhar B, Benter IF. Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PloS one 2012, 7(6).
37. Miura T, Miki T. GSK-3beta, a therapeutic target for cardiomyocyte protection. Circulat J Japan Circulat Soc 2009, 73(7):1184-1192.
38. Yin X, Zheng Y, Zhai X, Zhao X, Cai L. Diabetic inhibition of preconditioning- and postconditioning-mediated myocardial protection against ischemia/reperfusion injury. Exp Diabetes Res 2012, 2012:198048. 3148591, 21822424.
39. Yadav HN, Singh M, Sharma PL. Involvement of GSK-3beta in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heart. Mole Cell Biochem 2010, 343(1-2):75-81.